Demand
← Earnings Calls
01
02
03
04 05 06
Tone
AI
Capex
A1 A2
TMO
FY2026 Q2
Raised
Thermo Fisher Scientific Inc earnings call
Buzzberg read
Revenue grew 10% to $11.99 billion
Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance.
Buzzberg read Revenue grew 10% to $11.99 billion Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance. Read full analysisCollapse analysis
Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance.
- Full-year revenue guidance raised to $47.4-48.1B; EPS raised to $24.93-25.33.
- Pharma/biotech end market grew mid-single digits with strong bioproduction and clinical research.
- Academic/government grew low single digits, returning to growth; US positive.
Revenue$11.994B+9% QoQ
EPS$6.03+11% QoQ
Gross margin41.21%Reported
Operating margin17.4%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Margins
Adjusted operating margin expanded 90 bps to 22.8%
Guidance
Raised full-year revenue guidance to $47.4-$48.1B
Show 3 more callouts
Capital return
Deployed $1.2B to shareholders via buybacks and dividends
Demand
Bioproduction had another quarter of excellent growth
Other
Actively deploying AI across the company
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $11.994B | +9% QoQ |
| EPS | $6.03 | +11% QoQ |
| Gross margin | 41.21% | Reported |
| Operating margin | 17.4% | Reported |
| Free cash flow | $1.675B | Reported |
| Capex | $0.45B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $24.93–$25.33 | $25.13 | Raised |
| Revenue | FY2026 | $47.4B–$48.1B | $47.75B | Raised |
AI, capex & demand read
Management read
confident
Management struck a confident tone, citing an outstanding quarter, a clean top and bottom line beat, and raising full-year guidance. The tone was driven by strong customer activity across end markets and excellent operational execution.
Management AI read
Management discussed launching next-generation Orbitrap platforms and AI-driven capabilities at the ASMS conference, and stated they are actively deploying AI across the company to further accelerate PPI's impact.
Investment and capacity
Net capital expenditures for 2026 are expected to be between $1.9 and $2.1 billion; $800 million was spent in the first half. Management also noted they are increasing capacity for the filtration and separation business.
all 2 named companies below
Companiesreturns since call
Supply chain
Supply chain
Marc Casper
Electron microscopy strength partly attributed to semiconductor enabling role, with strong bookings growth. — Suggests ongoing capital equipment demand in semiconductor manufacturing, benefiting tool suppliers and potentially reinforcing capex cycle narratives.
Evidence
“Within electron microscopy, another really good quarter, semiconductor, we play a key enabling role there”
External signals
Supply-chain alpha · 2returns since call
Chemical analysis business growth was driven by higher commodity prices and increased demand for safety/security applications (radiation and explosives detection) due to global conflict.
Evidence
“We also saw an increase in demand for safety and security applications as well, given the amount of conflict going on in the world.”
Electron microscopy strength partly attributed to semiconductor enabling role, with strong bookings growth.
Methodology & coverage
Management-only analysis. All 2 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.